Childhood Cancer

You are here

Bad Influence: EWS/FLI Alters LSD1 and NuRD Interactions to Enforce Oncogenic Function in Ewing’s

Institution: 
Research Institute at Nationwide Children's Hospital
Researcher(s): 
Emily Theisen, PhD
Grant Type: 
Young Investigator Grants
Year Awarded: 
2016
Type of Childhood Cancer: 
Ewing Sarcoma
Project Description: 

Background 

Ewing’s sarcoma is an aggressive pediatric bone tumor characterized by the EWS/FLI fusion gene. While advances in multimodal therapy have raised disease-free survival rates above 70% for patients with localized disease, survival rates for in metastatic and refractory cases remain stuck below 30%. We need better therapeutic strategies for these patients. EWS/FLI remains challenging to treat with drugs directly and sequencing of patient tumors failed to identify additional drug-treatable mutations common across patients. 

This project studies the protein complexes assembled by EWS/FLI in the nucleus to activate tumor promoting genes and silence tumor suppressing genes. These complexes contain drug-treatable protein subunits, like histone deacetylases (HDACs) and HDAC inhibitors and those actively pursued as novel targets, such as lysine specific demethylase 1 (LSD1). Such "epigenetic" mechanisms are commonly co-opted to enforce tumorigenic gene expression in pediatric tumors with otherwise stable genomes. Epigenetic regulation is complex, context-dependent, and incompletely understood. Thus, while epigenetic therapies hold great promise for pediatric cancers and Ewing’s sarcoma specifically, our ability to implement effective clinical regimens is limited. 

Project Goal

This proposal focuses on the nucleosome remodeling and deacetylase (NuRD) and LSD1-containing complexes previously identified by our group as critical EWS/FLI co-conspirators. Moreover, pharmacological blockade of both NuRD and LSD1 impairs EWS/FLI-mediated gene regulation. We propose to define exactly how EWS/FLI alters NuRD and LSD1 function. Achieving this goal 1) furthers our ability to advance LSD1 inhibitors for Ewing’s sarcoma patients and 2) establishes a paradigm for linking deep basic science to drug-treatable epigenetic phenomena in mutationally quiet pediatric cancers.

"By prioritizing questions relevant to pediatric malignancies, Alex's Lemonade Stand Foundation enables young investigators to pursue routes of inquiry more impactful to patient care. The mechanisms which cause pediatric cancer not only matter to our young patients, but also illuminate the ways in which biology is altered in other diseases, and must not be overlooked. These research pursuits, while important, do not often garner the same level of government support as other major diseases. Support from ALSF during my early career enhances my ability to pursue these pressing questions and fosters my independent research career focused in pediatric cancer." - Emily Theisen, PhD

 

Co-funded by: 
Northwestern Mutual Foundation